During the last session, Lyra Therapeutics Inc (NASDAQ:LYRA)’s traded shares were 3.82 million, with the beta value of the company hitting -0.02. The 52-week high for the LYRA share is $6.79, that puts it down -2414.81 from that peak though still a striking 22.22% gain since the share price plummeted to a 52-week low of $0.21. The company’s market capitalization is $17.84M, and the average intraday trading volume over the past 10 days was 2.27 million shares, and the average trade volume was 999.04K shares over the past three months.
Lyra Therapeutics Inc (LYRA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.60. LYRA has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.23.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Lyra Therapeutics Inc (NASDAQ:LYRA) trade information
Lyra Therapeutics Inc (LYRA) registered a 2.83% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 2.83% in intraday trading to $0.27, hitting a weekly high. The stock’s 5-day price performance is -2.64%, and it has moved by 5.25% in 30 days. Based on these gigs, the overall price performance for the year is -91.09%. The short interest in Lyra Therapeutics Inc (NASDAQ:LYRA) is 2.14 million shares and it means that shorts have 3.65 day(s) to cover.
The consensus price target of analysts on Wall Street is $0.5, which implies an increase of 46.0% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $0.5 and $0.5 respectively. As a result, LYRA is trading at a discount of -85.19% off the target high and -85.19% off the low.
Lyra Therapeutics Inc (LYRA) estimates and forecasts
Statistics show that Lyra Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Lyra Therapeutics Inc (LYRA) shares have gone down -94.81% during the last six months, with a year-to-date growth rate less than the industry average at -19.51% against 17.50. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 14.80% this quarter and then jump 4.50% in the quarter after that. In the rating firms’ projections, revenue will increase 11.70% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 320k as predicted by 5 analyst(s). Meanwhile, a consensus of 5 analyst(s) estimates revenue growth to 330k by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 370k and 146k respectively. In this case, analysts expect current quarter sales to shrink by -13.50% and then jump by 126.00% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -21.63%. While earnings are projected to return -5.71% in 2024, the next five years will return -1.60% per annum.
LYRA Dividends
Lyra Therapeutics Inc is due to release its next quarterly earnings in November. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Lyra Therapeutics Inc (NASDAQ:LYRA)’s Major holders
Lyra Therapeutics Inc insiders own 0.66% of total outstanding shares while institutional holders control 58.92%, with the float percentage being 59.31%. PERCEPTIVE ADVISORS LLC is the largest shareholder of the company, while 73.0 institutions own stock in it. As of 2024-06-30, the company held over 12.76 million shares (or 19.9302% of all shares), a total value of $3.53 million in shares.
The next largest institutional holding, with 4.77 million shares, is of CITADEL ADVISORS LLC’s that is approximately 7.4562% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $1.32 million.
